Clinical Trial Update: Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on using calcifediol for prevention and treatment of COVID-19 induced acute respiratory syndrome; trial completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Release Syndrome
• Respiratory Distress Syndrome

Drugs mentioned

• Calcifediol (calcifediol (25-hydroxyvitamin D3))

Snippet

Sponsor: Maimónides Biomedical Research Institute of Córdoba | Conditions: SARS-CoV 2, COVID19 | Phase 2 | Status: COMPLETED